Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an announcement.
ImmuneOnco Biopharmaceuticals announced that Dr. Tian Wenzhi, the company’s executive director, CEO, and chairman, has increased his shareholding by purchasing 50,000 H shares in the open market. This move reflects Dr. Tian’s confidence in the company’s growth prospects and potential development, indicating a positive outlook for stakeholders.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in Shanghai, China. It focuses on the development and commercialization of innovative cancer immunotherapy products.
Average Trading Volume: 3,526,087
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$5.6B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.